Eterna Deferred Long Term Liab vs Current Deferred Revenue Analysis

ERNA Stock

USD 2.04 0.12 6.25%

Eterna Therapeutics financial indicator trend analysis is much more than just examining Eterna Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eterna Therapeutics is a good investment. Please check the relationship between Eterna Therapeutics Deferred Long Term Liab and its Current Deferred Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.

Deferred Long Term Liab vs Current Deferred Revenue

Deferred Long Term Liab vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eterna Therapeutics Deferred Long Term Liab account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Eterna Therapeutics' Deferred Long Term Liab and Current Deferred Revenue is 0.47. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Eterna Therapeutics, assuming nothing else is changed. The correlation between historical values of Eterna Therapeutics' Deferred Long Term Liab and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Eterna Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Deferred Long Term Liab i.e., Eterna Therapeutics' Deferred Long Term Liab and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.47

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Eterna Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eterna Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.As of June 6, 2024, Tax Provision is expected to decline to about 25 K. In addition to that, Selling General Administrative is expected to decline to about 13.6 M

	2021	2022	2023	2024 (projected)
Interest Expense	74K	30K	614K	644.7K
Depreciation And Amortization	459K	1.2M	1.1M	1.1M

Interest Expense Depreciation And Amortization

Eterna Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Debt	Intangible Assets	Common Stock	Other Liab
Total Assets		0.16	0.2	-0.26	0.92	-0.23	-0.3	0.94	0.06	0.33	0.96	0.44	0.88	0.88	-0.25	0.7	-0.71	0.37	0.5	0.5	-0.11	0.52	0.01	0.54	-0.22	0.61
Other Current Liab	0.16		0.42	0.68	0.03	0.86	0.26	-0.13	0.81	-0.31	-0.06	0.35	-0.02	0.03	-0.13	-0.09	-0.02	0.01	0.23	0.23	0.34	0.05	-0.19	-0.3	-0.23	0.34
Total Current Liabilities	0.2	0.42		0.15	0.04	0.33	-0.2	-0.02	0.52	0.17	0.13	0.43	0.17	0.09	0.55	0.12	-0.31	-0.09	0.17	0.17	0.36	-0.11	0.76	0.13	-0.34	0.4
Total Stockholder Equity	-0.26	0.68	0.15		-0.44	0.88	0.32	-0.55	0.65	-0.48	-0.52	0.37	-0.57	-0.5	0.03	-0.66	0.37	0.22	0.33	0.33	0.44	0.03	-0.35	-0.37	0.03	-0.21
Non Current Assets Total	0.92	0.03	0.04	-0.44		-0.4	-0.32	0.95	-0.15	0.25	0.95	0.06	0.95	0.98	-0.39	0.87	-0.59	0.25	0.17	0.17	-0.32	0.49	-0.01	0.58	-0.05	0.65
Non Currrent Assets Other	-0.23	0.86	0.33	0.88	-0.4		0.32	-0.51	0.81	-0.39	-0.46	0.34	-0.46	-0.4	0.07	-0.51	0.19	-0.05	0.21	0.21	0.45	-0.2	-0.23	-0.43	-0.23	0.01
Common Stock Shares Outstanding	-0.3	0.26	-0.2	0.32	-0.32	0.32		-0.33	0.28	-0.18	-0.36	-0.02	-0.32	-0.27	0.09	-0.25	0.25	-0.42	-0.18	-0.18	0.39	-0.31	-0.43	-0.82	-0.2	-0.1
Non Current Liabilities Total	0.94	-0.13	-0.02	-0.55	0.95	-0.51	-0.33		-0.22	0.42	0.99	0.22	0.92	0.92	-0.31	0.8	-0.69	0.28	0.32	0.32	-0.28	0.48	0.0	0.57	-0.15	0.54
Other Current Assets	0.06	0.81	0.52	0.65	-0.15	0.81	0.28	-0.22		-0.42	-0.14	0.51	-0.16	-0.13	0.34	-0.23	0.1	-0.21	0.24	0.24	0.49	-0.23	-0.03	-0.38	-0.22	0.02
Other Stockholder Equity	0.33	-0.31	0.17	-0.48	0.25	-0.39	-0.18	0.42	-0.42		0.44	0.27	0.36	0.29	0.1	0.27	-0.83	0.07	0.29	0.29	0.07	0.07	0.36	0.31	-0.67	0.49
Total Liab	0.96	-0.06	0.13	-0.52	0.95	-0.46	-0.36	0.99	-0.14	0.44		0.28	0.94	0.93	-0.23	0.81	-0.73	0.26	0.34	0.34	-0.22	0.45	0.12	0.58	-0.2	0.6
Total Current Assets	0.44	0.35	0.43	0.37	0.06	0.34	-0.02	0.22	0.51	0.27	0.28		0.04	0.0	0.26	-0.23	-0.45	0.37	0.89	0.89	0.47	0.21	0.07	0.04	-0.44	0.07
Short Long Term Debt Total	0.88	-0.02	0.17	-0.57	0.95	-0.46	-0.32	0.92	-0.16	0.36	0.94	0.04		0.98	-0.29	0.95	-0.65	0.07	0.06	0.06	-0.24	0.34	0.2	0.53	-0.13	0.73
Property Plant And Equipment Net	0.88	0.03	0.09	-0.5	0.98	-0.4	-0.27	0.92	-0.13	0.29	0.93	0.0	0.98		-0.32	0.94	-0.61	0.08	0.05	0.05	-0.26	0.35	0.07	0.51	-0.14	0.72
Current Deferred Revenue	-0.25	-0.13	0.55	0.03	-0.39	0.07	0.09	-0.31	0.34	0.1	-0.23	0.26	-0.29	-0.32		-0.26	0.02	-0.4	-0.04	-0.04	0.32	-0.43	0.54	-0.14	-0.27	-0.25
Net Debt	0.7	-0.09	0.12	-0.66	0.87	-0.51	-0.25	0.8	-0.23	0.27	0.81	-0.23	0.95	0.94	-0.26		-0.49	-0.14	-0.24	-0.24	-0.28	0.18	0.24	0.44	-0.04	0.71
Retained Earnings	-0.71	-0.02	-0.31	0.37	-0.59	0.19	0.25	-0.69	0.1	-0.83	-0.73	-0.45	-0.65	-0.61	0.02	-0.49		-0.13	-0.45	-0.45	-0.09	-0.14	-0.25	-0.42	0.74	-0.73
Accounts Payable	0.37	0.01	-0.09	0.22	0.25	-0.05	-0.42	0.28	-0.21	0.07	0.26	0.37	0.07	0.08	-0.4	-0.14	-0.13		0.7	0.7	-0.24	0.82	-0.2	0.56	0.29	-0.08
Cash	0.5	0.23	0.17	0.33	0.17	0.21	-0.18	0.32	0.24	0.29	0.34	0.89	0.06	0.05	-0.04	-0.24	-0.45	0.7		1.0	0.16	0.52	-0.14	0.23	-0.28	0.01
Cash And Short Term Investments	0.5	0.23	0.17	0.33	0.17	0.21	-0.18	0.32	0.24	0.29	0.34	0.89	0.06	0.05	-0.04	-0.24	-0.45	0.7	1.0		0.16	0.52	-0.14	0.23	-0.28	0.01
Net Receivables	-0.11	0.34	0.36	0.44	-0.32	0.45	0.39	-0.28	0.49	0.07	-0.22	0.47	-0.24	-0.26	0.32	-0.28	-0.09	-0.24	0.16	0.16		-0.5	0.13	-0.38	-0.44	0.05
Good Will	0.52	0.05	-0.11	0.03	0.49	-0.2	-0.31	0.48	-0.23	0.07	0.45	0.21	0.34	0.35	-0.43	0.18	-0.14	0.82	0.52	0.52	-0.5		-0.23	0.48	0.36	0.1
Short Term Debt	0.01	-0.19	0.76	-0.35	-0.01	-0.23	-0.43	0.0	-0.03	0.36	0.12	0.07	0.2	0.07	0.54	0.24	-0.25	-0.2	-0.14	-0.14	0.13	-0.23		0.29	-0.17	0.24
Intangible Assets	0.54	-0.3	0.13	-0.37	0.58	-0.43	-0.82	0.57	-0.38	0.31	0.58	0.04	0.53	0.51	-0.14	0.44	-0.42	0.56	0.23	0.23	-0.38	0.48	0.29		0.16	0.28
Common Stock	-0.22	-0.23	-0.34	0.03	-0.05	-0.23	-0.2	-0.15	-0.22	-0.67	-0.2	-0.44	-0.13	-0.14	-0.27	-0.04	0.74	0.29	-0.28	-0.28	-0.44	0.36	-0.17	0.16		-0.49
Other Liab	0.61	0.34	0.4	-0.21	0.65	0.01	-0.1	0.54	0.02	0.49	0.6	0.07	0.73	0.72	-0.25	0.71	-0.73	-0.08	0.01	0.01	0.05	0.1	0.24	0.28	-0.49

Click cells to compare fundamentals

Eterna Therapeutics Account Relationship Matchups

Eterna Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.3M	12.9M	32.4M	22.3M	49.1M	51.6M
Other Current Liab	1.6M	975K	247K	4.0M	3.1M	2.0M
Total Current Liabilities	6.1M	3.1M	3.7M	7.7M	6.6M	5.9M
Total Stockholder Equity	5.1M	7.7M	6.5M	12.1M	2.2M	2.1M
Non Current Assets Total	9.2M	11.2M	13.7M	8.6M	39.5M	41.5M
Non Currrent Assets Other	2.3M	453K	522K	5.2M	120K	114K
Common Stock Shares Outstanding	71.9K	439.7K	2.2M	3.1M	5.3M	5.0M
Liabilities And Stockholders Equity	15.3M	12.9M	32.4M	22.3M	49.1M	51.6M
Non Current Liabilities Total	4.1M	2.1M	22.3M	2.5M	40.3M	42.3M
Other Current Assets	526K	102K	1.1M	2.2M	1.6M	2.3M
Other Stockholder Equity	136.3M	(245K)	165.9M	177.4M	189.2M	131.8M
Total Liab	10.2M	5.2M	25.9M	10.2M	46.9M	49.2M
Total Current Assets	6.1M	1.7M	18.8M	13.7M	9.6M	9.8M
Short Long Term Debt Total	6.1M	2.9M	2.7M	4.1M	41.8M	43.9M
Property Plant And Equipment Net	4.7M	4.9M	2.7M	1.3M	33.3M	34.9M
Current Deferred Revenue	460K	76K	1.2M	190K	218.5K	207.6K
Net Debt	2.8M	1.3M	(14.3M)	(7.3M)	34.3M	36.0M
Retained Earnings	(131.5M)	(18.1M)	(159.7M)	(165.3M)	(187.0M)	(196.3M)
Accounts Payable	835K	1.3M	1.8M	1.6M	1.1M	764.4K
Cash	3.3M	1.6M	17.0M	11.4M	7.6M	6.1M
Cash And Short Term Investments	3.3M	1.6M	17.0M	11.4M	7.6M	6.1M
Net Receivables	1.2M	116K	684K	951K	425K	678.2K
Good Will	1.0M	667K	696K	2.0M	2.4M	1.4M
Accumulated Other Comprehensive Income	200K	268K	245K	(1K)	(900.0)	(855.0)
Short Term Debt	3.2M	799K	426K	2.0M	2.2M	1.5M
Other Liab	930.4K	23K	48K	1.6M	1.9M	2.0M
Net Tangible Assets	7.7M	5.6M	23.5M	10.1M	11.6M	12.1M
Other Assets	7.3M	6.4M	1K	5.2M	4.7M	4.2M
Property Plant Equipment	653.8K	2.7M	3.2M	1.3M	1.5M	1.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VTSNX	Vanguard Total International
VBTIX	Vanguard Total Bond
VMCIX	Vanguard Mid Cap Index

Additional Information and Resources on Investing in Eterna Stock

When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:

How To Invest In Eterna

Details

Is Eterna Stock a good investment?

Details

What is Eterna Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.25)

Revenue Per Share

0.021

Return On Assets

(0.41)

Return On Equity

(11.54)

The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eterna Deferred Long Term Liab vs Current Deferred Revenue Analysis

Deferred Long Term Liab vs Current Deferred Revenue

Deferred Long Term Liab vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Current Deferred Revenue

Eterna Therapeutics fundamental ratios Correlations

Eterna Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eterna Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Information and Resources on Investing in Eterna Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Non Current Liabilities Total
Property Plant And Equipment Net	+ 0.98	Non Current Assets Total
Property Plant And Equipment Net	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.96	Total Assets
Non Current Liabilities Total	+ 0.95	Non Current Assets Total

Retained Earnings	- 0.83	Other Stockholder Equity
Intangible Assets	- 0.82	Common Stock Shares Outstanding
Other Liab	- 0.73	Retained Earnings
Retained Earnings	- 0.73	Total Liab
Retained Earnings	- 0.71	Total Assets
Retained Earnings	- 0.69	Non Current Liabilities Total